Status:
TERMINATED
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone o...
Eligibility Criteria
Inclusion
- NSCLC who are eligible to receive a 6 week course of RT
- Part 1 - not candidates for definitive RT
- Part 2 - candidates for definitive RT
Exclusion
- Severe COPD, pulmonary infection or interstitial pneumonitis
- Recent cellulitis
- Autoimmune disease
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2009
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00461110
Start Date
January 1 2008
End Date
April 1 2009
Last Update
September 4 2009
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cancer Institute Of New Jersey
New Brunswick, New Jersey, United States, 08901
2
Nyu Clinical Cancer Center
New York, New York, United States, 10016
3
Thomas Jefferson Univ Hospital
Philadelphia, Pennsylvania, United States, 19107
4
University Of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390